Beam Therapeutics Inc (BEAM) — Cash Flow Reinvestment Rate

Latest as of December 2023: 0.75x

Beam Therapeutics Inc (BEAM) has a Cash Flow Reinvestment Rate of 0.75x as of December 2023, reinvesting $101.69 Million (capex $3.59 Million plus investments $98.10 Million) from operating cash flow of $135.07 Million. Check Beam Therapeutics Inc earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.

Reinvestment Rate

0.75x
(Capex + Investments) / Operating CF

Total Reinvested

$101.69 Million
Capex + Investments

Operating Cash Flow

$135.07 Million
USD

Capital Expenditures

$3.59 Million
USD

Beam Therapeutics Inc Cash Flow Reinvestment Rate (2022–2022)

Historical reinvestment intensity for Beam Therapeutics Inc across 1 annual periods. Explore BEAM strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.

Annual Cash Flow Reinvestment Rate for Beam Therapeutics Inc (2022–2022)

Year-by-year capital reinvestment analysis for Beam Therapeutics Inc. For live market cap and broader valuation context, see Beam Therapeutics Inc (BEAM) market capitalisation.

Year Reinvestment Rate Total Reinvested (USD) Operating CF Capex YoY Change
2022 22.65x $510.29 Million $22.53 Million $48.95 Million
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow